description) This is an initial application submitted by a new investigator. Primary dysmenorrhea is defined as pain during the menses in the absence of a pathologic lesion and is probably caused by prostaglandin effects on the uterus. Primary dysmenorrhea is highly prevalent among adolescents. More than 50% of adolescent girls in various populations report dysmenorrhea which is severe in about 15%. Dysmenorrhea is a major cause of morbidity in adolescents leading to activity restriction and school absence. Combined oral contraceptives (COC) are a common treatment for primary dysmenorrhea. Some small laboratory studies show decreased prostaglandins associated with COC use compared to non-COC use. Larger observational studies show a lower prevalence of dysmenorrhea among COC users compared to non-COC users and improved dysmenorrhea after initiating open-label COC use. In the only randomized, double blind, placebo-controlled trial, Matthews showed modest improvement of dysmenorrhea among a small number of women using a high- dose COC compared to placebo (1968). None of the existing studies compare the efficacy of a low-dose COC with placebo in the treatment of primary dysmenorrhea. The proposed study is a double blind, randomized, placebo-controlled trial to determine the efficacy of a low-dose COC in the treatment of primary dysmenorrhea among urban, adolescent girls. Healthy girls aged 19 years or less with moderate to severe dysmenorrhea as determined by the Robinson modification of the Andersch scale will be eligible (Robinson, 1992). 150 girls will be randomized to receive either a COC containing 20 micrograms ethinyl estradiol and 0.1 milligrams levonorgestrel or a placebo. The main effect will be change in score on the pain sub-scale of the Moos Menstrual Distress Questionnaire (MDQ) after three months of treatment. This study will have 80% power to detect a 50% reduction in pain score with an alpha of .05 and a drop-out rate of 40%. Secondary outcome measures will be changes in school absence, activity restriction and medication use. Also, we plan to determine if psychological measures of depression, life-crisis events or self- concept ratings predict response to treatment. Given their efficacy in pregnancy prevention, safety, and non-contraceptive health benefits, COC may be an ideal therapy for primary dysmenorrhea in adolescent girls.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Small Research Grants (R03)
Project #
1R03HD039776-01
Application #
6230007
Study Section
Pediatrics Subcommittee (CHHD)
Program Officer
Kaufman, Steven
Project Start
2001-04-01
Project End
2003-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
1
Fiscal Year
2001
Total Cost
$81,750
Indirect Cost
Name
Columbia University (N.Y.)
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
O'Connell, Katharine; Davis, Anne R; Kerns, Jennifer (2007) Oral contraceptives: side effects and depression in adolescent girls. Contraception 75:299-304
Davis, Anne R; Osborne, Lauren M; O'Connell, Katharine J et al. (2006) Challenges of conducting a placebo-controlled trial for dysmenorrhea in adolescents. J Adolesc Health 39:607-9
O'Connell, Katharine; Davis, Anne Rachel; Westhoff, Carolyn (2006) Self-treatment patterns among adolescent girls with dysmenorrhea. J Pediatr Adolesc Gynecol 19:285-9
Davis, Anne Rachel; Westhoff, Carolyn; O'Connell, Katharine et al. (2005) Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol 106:97-104